Quarterly ResultMay 7, 2026, 04:08 PM
Jade Biosciences Q1 Net Loss $40.4M; Advances 3 Clinical Programs
AI Summary
Jade Biosciences reported a net loss of $40.4 million for the first quarter ended March 31, 2026, an increase from $38.2 million in the prior year, driven by higher R&D and G&A expenses. The company announced significant pipeline progress, including the presentation of interim Phase 1 data for JADE101 and the expected initiation of Phase 2 for JADE101 and Phase 1 for JADE201 in Q2 2026. JADE301's Phase 1 trial is on track for H1 2027, and the company appointed Edward R. Conner, M.D., as Chief Medical Officer. Jade Biosciences holds $311.3 million in cash, providing a runway into the first half of 2028.
Key Highlights
- Interim Phase 1 data for JADE101 to be presented at the 63rd European Renal Association Congress.
- Phase 2 clinical trial for JADE101 in IgA nephropathy patients expected to begin in Q2 2026.
- Phase 1 clinical trial for JADE201 expected to begin in Q2 2026, with interim data in 2027.
- Q1 2026 net loss totaled $40.4 million, compared to $38.2 million in Q1 2025.
- R&D expenses increased to $36.1 million in Q1 2026 from $20.0 million in Q1 2025.
- Cash, cash equivalents, and investments were $311.3 million as of March 31, 2026.
- Existing cash expected to provide runway into the first half of 2028.
- Edward R. Conner, M.D., appointed as Chief Medical Officer.